Science and Research

The effect of antibiotic therapy on clinical outcome in patients hospitalized with moderate COVID-19 disease: a prospective multi-center cohort study

PURPOSE: The benefit of antibiotic treatment (ABT) for patients with moderate COVID-19 is unclear and overtreatment poses the risk of adverse effects such as Clostridioides difficile infection and antibiotic resistance. This multi-center study compares health status improvement between patients with and without ABT at hospital admission. METHODS: Between March 2020 and May 2023, hospitalized adults with confirmed SARS-CoV-2 infection were recruited from the German National Pandemic Cohort Network (NAPKON), which includes patients from various hospitals across Germany. The study population included patients with moderate or severe COVID-19 at baseline. The primary objective was to compare health improvement or decline after two weeks between patients who received ABT at baseline and those who did not in the moderate COVID-19 population. The statistical analysis adjusted for confounders such as gender, age, vaccination status, clinical condition, and comorbidities. The severe COVID-19 population was investigated as a secondary objective. RESULTS: A total of 1,317 patients (median age 59 years; 38% women) were eligible for analysis, of whom 1,149 had moderate and 168 severe COVID-19 disease. ABT for pneumonia was administered to 467 patients with moderate and 117 with severe COVID-19. ABT at baseline was significantly associated with a higher deterioration rate after two weeks in patients with moderate COVID-19 (ABT: 292 improvement, 61 deterioration; no ABT: 429 improvement, 14 deterioration). A similar result was obtained in the multiple regression analysis where an odds ratio of 5.00 (95% confidence interval: 2.50 - 10.93) for ABT was observed. CONCLUSION: We found no benefit of antibiotic therapy in patients with moderate COVID-19. Use of ABT was associated with a higher likelihood of clinical deterioration.

  • Friedrichs, A.
  • Wenz, R.
  • Pape, D.
  • Appel, K. S.
  • Bahmer, T.
  • Becker, K.
  • Bercker, S.
  • Blaschke, S.
  • Braunsteiner, J.
  • Butzmann, J.
  • Dahl, E.
  • Erber, J.
  • Fricke, L.
  • Geisler, R.
  • Göpel, S.
  • Güldner, A.
  • Hagen, M.
  • Hamprecht, A.
  • Hansch, S.
  • Heuschmann, P. U.
  • Hopff, S.
  • Jensen, B. O.
  • Käding, N.
  • Koepsell, J.
  • Koll, C. E. M.
  • Krawczyk, M.
  • Lücke, T.
  • Meybohm, P.
  • Milovanovic, M.
  • Mitrov, L.
  • Nürnberger, C.
  • Römmele, C.
  • Scherer, M.
  • Schmidbauer, L.
  • Stecher, M.
  • Tepasse, P. R.
  • Teufel, A.
  • Vehreschild, J. J.
  • Winter, C.
  • Witzke, O.
  • Wyen, C.
  • Hanses, F.
  • Caliebe, A.

Keywords

  • Covid-19
  • Clinical improvement
  • Clinical outcome
  • Moderate disease
  • Rational antibiotic therapy
Publication details
DOI: 10.1007/s15010-025-02590-0
Journal: Infection
Work Type: Original
Location: Assoziierter Partner, ARCN
Disease Area: PALI
Partner / Member: Ghd, UKSH (Kiel)
Access-Number: 40569348


chevron-down